(CYTK) Cytokinetics - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US23282W6057
Stock: Muscle Activators, Muscle Inhibitors, Heart Failure, Cardiac Myosin
Total Rating 34
Risk 30
Buy Signal -0.70
| Risk 5d forecast | |
|---|---|
| Volatility | 53.7% |
| Relative Tail Risk | -16.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.76 |
| Alpha | 19.22 |
| Character TTM | |
|---|---|
| Beta | 1.141 |
| Beta Downside | 1.026 |
| Drawdowns 3y | |
|---|---|
| Max DD | 72.39% |
| CAGR/Max DD | 0.27 |
EPS (Earnings per Share)
Revenue
Description: CYTK Cytokinetics March 05, 2026
Cytokinetics, Inc. is a late-stage biopharmaceutical company. It specializes in developing muscle activators and inhibitors for debilitating diseases. The biopharmaceutical sector is characterized by lengthy and capital-intensive drug development processes.
The companys pipeline includes omecamtiv mecarbil, a cardiac myosin activator in Phase III for heart failure. Other drug candidates are CK-089 (skeletal muscle troponin activator, Phase I), CK-586 (cardiac myosin inhibitor, Phase II), and aficamten (cardiac myosin inhibitor, Phase III) for hypertrophic cardiomyopathy. This business model relies on successful clinical trials and regulatory approvals.
Cytokinetics has strategic alliances, including one with Ji Xing Pharmaceuticals Limited and a collaboration with an unnamed entity for aficamtens development and commercialization in Japan. The company was founded in 1997 and is based in South San Francisco, California.
To understand the full scope of CYTKs market position, explore its detailed financials and competitive landscape on ValueRay.
Headlines to watch out for
- MYQORZO sales drive revenue growth
- Aficamten regulatory approval impacts future sales
- Clinical trial results for pipeline drugs affect valuation
- Healthcare policy changes influence drug pricing
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income: -785.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.38 > 0.02 and ΔFCF/TA -9.02 > 1.0 |
| NWC/Revenue: 811.6% < 20% (prev 5025 %; Δ -4213 % < -1%) |
| CFO/TA -0.36 > 3% & CFO -510.0m > Net Income -785.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.53 > 1.5 & < 3 |
| Outstanding Shares: last quarter (122.4m) vs 12m ago 3.69% < -2% |
| Gross Margin: -22.29% > 18% (prev -17.37%; Δ -492.1% > 0.5%) |
| Asset Turnover: 6.23% > 50% (prev 1.32%; Δ 4.91% > 0%) |
| Interest Coverage Ratio: -6.85 > 6 (EBITDA TTM -701.5m / Interest Expense TTM 103.9m) |
Altman Z'' -9.83
| A: 0.50 (Total Current Assets 917.0m - Total Current Liabilities 202.5m) / Total Assets 1.42b |
| B: -2.45 (Retained Earnings -3.49b / Total Assets 1.42b) |
| C: -0.50 (EBIT TTM -711.4m / Avg Total Assets 1.41b) |
| D: -1.67 (Book Value of Equity -3.49b / Total Liabilities 2.08b) |
| Altman-Z'' Score: -9.83 = D |
Beneish M -0.41
| DSRI: 0.22 (Receivables 17.8m/16.6m, Revenue 88.0m/18.5m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 2.27 (AQ_t 0.25 / AQ_t-1 0.11) |
| SGI: 4.77 (Revenue 88.0m / 18.5m) |
| TATA: -0.19 (NI -785.0m - CFO -510.0m) / TA 1.42b) |
| Beneish M-Score: -0.41 (Cap -4..+1) = D |
What is the price of CYTK shares?
As of March 09, 2026, the stock is trading at USD 60.41 with a total of 1,762,045 shares traded.
Over the past week, the price has changed by -1.66%, over one month by -4.66%, over three months by -5.80% and over the past year by +39.48%.
Over the past week, the price has changed by -1.66%, over one month by -4.66%, over three months by -5.80% and over the past year by +39.48%.
Is CYTK a buy, sell or hold?
Cytokinetics has received a consensus analysts rating of 4.29.
Therefore, it is recommended to buy CYTK.
- StrongBuy: 9
- Buy: 9
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CYTK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 91.2 | 50.9% |
| Analysts Target Price | 91.2 | 50.9% |
CYTK Fundamental Data Overview March 07, 2026
P/E Forward = 117.6471
P/S = 86.3669
P/B = 60.5261
P/EG = -0.42
Revenue TTM = 88.0m USD
EBIT TTM = -711.4m USD
EBITDA TTM = -701.5m USD
Long Term Debt = 1.12b USD (from longTermDebt, last quarter)
Short Term Debt = 60.3m USD (from shortTermDebt, last quarter)
Debt = 1.28b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 402.0m USD (from netDebt column, last quarter)
Enterprise Value = 8.01b USD (7.60b + Debt 1.28b - CCE 882.2m)
Interest Coverage Ratio = -6.85 (Ebit TTM -711.4m / Interest Expense TTM 103.9m)
EV/FCF = -14.97x (Enterprise Value 8.01b / FCF TTM -534.8m)
FCF Yield = -6.68% (FCF TTM -534.8m / Enterprise Value 8.01b)
FCF Margin = -607.5% (FCF TTM -534.8m / Revenue TTM 88.0m)
Net Margin = -891.6% (Net Income TTM -785.0m / Revenue TTM 88.0m)
Gross Margin = -22.29% ((Revenue TTM 88.0m - Cost of Revenue TTM 107.7m) / Revenue TTM)
Gross Margin QoQ = 83.89% (prev -38.38%)
Tobins Q-Ratio = 5.62 (Enterprise Value 8.01b / Total Assets 1.42b)
Interest Expense / Debt = 2.36% (Interest Expense 30.3m / Debt 1.28b)
Taxrate = 21.0% (US default 21%)
NOPAT = -562.0m (EBIT -711.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.53 (Total Current Assets 917.0m / Total Current Liabilities 202.5m)
Debt / Equity = -1.95 (negative equity) (Debt 1.28b / totalStockholderEquity, last quarter -659.6m)
Debt / EBITDA = -0.57 (negative EBITDA) (Net Debt 402.0m / EBITDA -701.5m)
Debt / FCF = -0.75 (negative FCF - burning cash) (Net Debt 402.0m / FCF TTM -534.8m)
Total Stockholder Equity = -454.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -55.55% (Net Income -785.0m / Total Assets 1.42b)
RoE = 172.9% (negative equity) (Net Income TTM -785.0m / Total Stockholder Equity -454.0m)
RoCE = -107.5% (out of range, set to none) (EBIT -711.4m / Capital Employed (Equity -454.0m + L.T.Debt 1.12b))
RoIC = -125.4% (out of range, set to none) (NOPAT -562.0m / Invested Capital 448.1m)
WACC = 8.93% (E(7.60b)/V(8.89b) * Re(10.12%) + D(1.28b)/V(8.89b) * Rd(2.36%) * (1-Tc(0.21)))
Discount Rate = 10.12% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 11.17%
[DCF] Fair Price = unknown (Cash Flow -534.8m)
EPS Correlation: -49.05 | EPS CAGR: -8.67% | SUE: 0.16 | # QB: 0
Revenue Correlation: 11.72 | Revenue CAGR: 107.6% | SUE: 0.29 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-1.64 | Chg7d=-0.114 | Chg30d=-0.067 | Revisions Net=-1 | Analysts=11
EPS current Year (2026-12-31): EPS=-6.44 | Chg7d=-0.368 | Chg30d=-0.497 | Revisions Net=-1 | Growth EPS=+1.5% | Growth Revenue=+0.8%
EPS next Year (2027-12-31): EPS=-4.66 | Chg7d=-0.704 | Chg30d=-0.704 | Revisions Net=+0 | Growth EPS=+27.7% | Growth Revenue=+333.3%
[Analyst] Revisions Ratio: -0.20 (2 Up / 3 Down within 30d for Next Quarter)
P/S = 86.3669
P/B = 60.5261
P/EG = -0.42
Revenue TTM = 88.0m USD
EBIT TTM = -711.4m USD
EBITDA TTM = -701.5m USD
Long Term Debt = 1.12b USD (from longTermDebt, last quarter)
Short Term Debt = 60.3m USD (from shortTermDebt, last quarter)
Debt = 1.28b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 402.0m USD (from netDebt column, last quarter)
Enterprise Value = 8.01b USD (7.60b + Debt 1.28b - CCE 882.2m)
Interest Coverage Ratio = -6.85 (Ebit TTM -711.4m / Interest Expense TTM 103.9m)
EV/FCF = -14.97x (Enterprise Value 8.01b / FCF TTM -534.8m)
FCF Yield = -6.68% (FCF TTM -534.8m / Enterprise Value 8.01b)
FCF Margin = -607.5% (FCF TTM -534.8m / Revenue TTM 88.0m)
Net Margin = -891.6% (Net Income TTM -785.0m / Revenue TTM 88.0m)
Gross Margin = -22.29% ((Revenue TTM 88.0m - Cost of Revenue TTM 107.7m) / Revenue TTM)
Gross Margin QoQ = 83.89% (prev -38.38%)
Tobins Q-Ratio = 5.62 (Enterprise Value 8.01b / Total Assets 1.42b)
Interest Expense / Debt = 2.36% (Interest Expense 30.3m / Debt 1.28b)
Taxrate = 21.0% (US default 21%)
NOPAT = -562.0m (EBIT -711.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.53 (Total Current Assets 917.0m / Total Current Liabilities 202.5m)
Debt / Equity = -1.95 (negative equity) (Debt 1.28b / totalStockholderEquity, last quarter -659.6m)
Debt / EBITDA = -0.57 (negative EBITDA) (Net Debt 402.0m / EBITDA -701.5m)
Debt / FCF = -0.75 (negative FCF - burning cash) (Net Debt 402.0m / FCF TTM -534.8m)
Total Stockholder Equity = -454.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -55.55% (Net Income -785.0m / Total Assets 1.42b)
RoE = 172.9% (negative equity) (Net Income TTM -785.0m / Total Stockholder Equity -454.0m)
RoCE = -107.5% (out of range, set to none) (EBIT -711.4m / Capital Employed (Equity -454.0m + L.T.Debt 1.12b))
RoIC = -125.4% (out of range, set to none) (NOPAT -562.0m / Invested Capital 448.1m)
WACC = 8.93% (E(7.60b)/V(8.89b) * Re(10.12%) + D(1.28b)/V(8.89b) * Rd(2.36%) * (1-Tc(0.21)))
Discount Rate = 10.12% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 11.17%
[DCF] Fair Price = unknown (Cash Flow -534.8m)
EPS Correlation: -49.05 | EPS CAGR: -8.67% | SUE: 0.16 | # QB: 0
Revenue Correlation: 11.72 | Revenue CAGR: 107.6% | SUE: 0.29 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-1.64 | Chg7d=-0.114 | Chg30d=-0.067 | Revisions Net=-1 | Analysts=11
EPS current Year (2026-12-31): EPS=-6.44 | Chg7d=-0.368 | Chg30d=-0.497 | Revisions Net=-1 | Growth EPS=+1.5% | Growth Revenue=+0.8%
EPS next Year (2027-12-31): EPS=-4.66 | Chg7d=-0.704 | Chg30d=-0.704 | Revisions Net=+0 | Growth EPS=+27.7% | Growth Revenue=+333.3%
[Analyst] Revisions Ratio: -0.20 (2 Up / 3 Down within 30d for Next Quarter)